Side effects suicide

The warning signs were there in 2008. The FDA knew. The drugmaker knew.

Yet, for years, millions of children and adults continued to be prescribed the asthma and allergy drug Singulair (montelukast), unaware of its potential to cause devastating psychiatric side effects.

We're now confronting a haunting reality in 2025: reports of suicide, suicidal thoughts, severe depression, anxiety, hallucinations, and aggressive behavior in patients taking this still-common medication.

One mother's story echoes a tragedy faced by too many: her healthy 15-year-old son ended his life just 17 days after starting the drug.

As of November 2025:
- Singulair still carries the FDA’s strongest black-box warning for neuropsychiatric events (added in 2020 and unchanged since).
- A major FDA study released in November 2024 confirmed the drug crosses into the brain and binds to receptors linked to mood, impulse control, and sleep — explaining why symptoms can appear in days.
- Over 82 confirmed suicides (including dozens of children and teens) and thousands of severe psychiatric reports have been linked to the drug since 1998.
- Hundreds of lawsuits against Merck and current maker Organon are active, accusing the companies of hiding risks for profit.
- Doctors are now urged to prescribe it only when other options fail, and to stop it immediately if any mental health changes appear.

Why did it take until 2020 for a black-box warning? Why are kids still getting this drug in 2025? Why has no major settlement or recall happened?

This isn't just a medical issue — it’s a profound failure of patient safety and corporate accountability.

The full 2008 report and the subsequent inaction reveal a story the public must hear.
Share to demand answers, stronger warnings, and real justice for the families shattered by Singulair.

t.me/WikiLeaksOrganisation
Recommended Channels: Click here